Cargando…

Human pancreatic adenocarcinoma contains a side population resistant to gemcitabine

BACKGROUND: Therapy resistance remains one of the major challenges to improve the prognosis of patients with pancreatic cancer. Chemoresistant cells, which potentially also display cancer stem cell (CSC) characteristics, can be isolated using the side population (SP) technique. Our aim was to search...

Descripción completa

Detalles Bibliográficos
Autores principales:	Van den broeck, Anke, Gremeaux, Lies, Topal, Baki, Vankelecom, Hugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3500221/ https://www.ncbi.nlm.nih.gov/pubmed/22894607 http://dx.doi.org/10.1186/1471-2407-12-354

Ejemplares similares

Human Pancreatic Cancer Contains a Side Population Expressing Cancer Stem Cell-Associated and Prognostic Genes
por: Van den broeck, Anke, et al.
Publicado: (2013)

Molecular markers associated with outcome and metastasis in human pancreatic cancer
por: Van den Broeck, Anke, et al.
Publicado: (2012)

The Human Melanoma Side Population Displays Molecular and Functional Characteristics of Enriched Chemoresistance and Tumorigenesis
por: Wouters, Jasper, et al.
Publicado: (2013)

Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma
por: Janky, Rekin’s, et al.
Publicado: (2016)

A phase I radiation dose-escalation study to determine the maximal dose of radiotherapy in combination with weekly gemcitabine in patients with locally advanced pancreatic adenocarcinoma
por: Budiharto, Tom, et al.
Publicado: (2008)

Survival After Minimally Invasive vs Open Surgery for Pancreatic Adenocarcinoma
por: Topal, Halit, et al.
Publicado: (2022)

Systematic exploration of the underlying mechanism of gemcitabine resistance in pancreatic adenocarcinoma
por: Liu, Kaidong, et al.
Publicado: (2022)

Gemcitabine Recruits M2-Type Tumor-Associated Macrophages into the Stroma of Pancreatic Cancer
por: Bulle, Ashenafi, et al.
Publicado: (2020)

A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma
por: Hu, Jing, et al.
Publicado: (2011)

Integrated stress response is critical for gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Palam, L R, et al.
Publicado: (2015)

Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma
por: Shao, Feng, et al.
Publicado: (2018)

Resistance to Gemcitabine in Pancreatic Ductal Adenocarcinoma: A Physiopathologic and Pharmacologic Review
por: Koltai, Tomas, et al.
Publicado: (2022)

Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma
por: Nishi, Hidemi, et al.
Publicado: (2023)

Gemcitabine and oxaliplatin (GEMOX) in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study
por: Demols, A, et al.
Publicado: (2006)

Lipocalin2 Promotes Invasion, Tumorigenicity and Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Leung, Lisa, et al.
Publicado: (2012)

Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase
por: Amit, Moran, et al.
Publicado: (2013)

Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma
por: Miller, Aubrey L., et al.
Publicado: (2020)

Real‐world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma
por: de Jong, Evelien J. M., et al.
Publicado: (2021)

Survivin Splice Variant 2β Enhances Pancreatic Ductal Adenocarcinoma Resistance to Gemcitabine
por: Fuller, Ryan N, et al.
Publicado: (2022)

Pancreatic ductal adenocarcinoma cells regulated the gemcitabine‐resistance function of CAFs by LINC00460
por: Zhu, Xiao‐Xu, et al.
Publicado: (2022)

Real-world outcomes of adjuvant gemcitabine versus gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
por: Kang, Sora, et al.
Publicado: (2022)

Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma
por: Sun, Qiqing, et al.
Publicado: (2019)

MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma
por: Mikamori, Manabu, et al.
Publicado: (2017)

Perioperative cancer cell dissemination detected with a real-time RT-PCR assay for EpCAM is not associated with worse prognosis in pancreatic ductal adenocarcinoma
por: Sergeant, Gregory, et al.
Publicado: (2011)

Understanding the Mechanism of Cell Death in Gemcitabine Resistant Pancreatic Ductal Adenocarcinoma: A Systems Biology Approach
por: Aier, Imlimaong, et al.
Publicado: (2019)

Novel crosstalk between KLF4 and ZEB1 regulates gemcitabine resistance in pancreatic ductal adenocarcinoma
por: Wang, Zhiyi, et al.
Publicado: (2020)

OXCT1 Enhances Gemcitabine Resistance Through NF-κB Pathway in Pancreatic Ductal Adenocarcinoma
por: Ding, Jinsheng, et al.
Publicado: (2021)

Anti-Bv8 Antibody and Metronomic Gemcitabine Improve Pancreatic Adenocarcinoma Treatment Outcome Following Weekly Gemcitabine Therapy()()
por: Hasnis, Erez, et al.
Publicado: (2014)

Identification of a Novel Subpopulation of Tumor-Initiating Cells from Gemcitabine-Resistant Pancreatic Ductal Adenocarcinoma Patients
por: Shimizu, Kazuya, et al.
Publicado: (2013)

LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
por: Zhu, Yin-Xin, et al.
Publicado: (2020)

Andrographis Reverses Gemcitabine Resistance through Regulation of ERBB3 and Calcium Signaling Pathway in Pancreatic Ductal Adenocarcinoma
por: Okuno, Keisuke, et al.
Publicado: (2023)

Contribution of FKBP5 Genetic Variation to Gemcitabine Treatment and Survival in Pancreatic Adenocarcinoma
por: Ellsworth, Katarzyna A., et al.
Publicado: (2013)

Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma
por: Middleton, Gary, et al.
Publicado: (2016)

Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
por: Li, Junjie, et al.
Publicado: (2018)

Digital Ischemia and Necrosis: A Rarely Described Complication of Gemcitabine in Pancreatic Adenocarcinoma
por: So, Eiichiro, et al.
Publicado: (2017)

Evaluation of gemcitabine efficacy after the FOLFIRINOX regimen in patients with advanced pancreatic adenocarcinoma
por: Gilabert, Marine, et al.
Publicado: (2017)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Establishment and characterization of the gemcitabine-resistant human pancreatic cancer cell line SW1990/gemcitabine
por: Yu, Yue, et al.
Publicado: (2019)

Correction: Clusterin confers gemcitabine resistance in pancreatic cancer
por: Chen, Qingfeng, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_g1fojc3ki1p0t2kj9jjevr6bm2